Using individual biomarkers to improve lymphoma treatment
Interest of Individual Biomarkers From the Identification of Tumor Genotype in Plasma (ctDNA: Circulating Tumor DNA) by High-throughput Molecular Next Generation Techniques(CAPP Seq, PhAsE Seq, VIRCAPP-seq) in the Diagnosis and Personalized Management of Lymphomas in a Prospective Monocentric Cohort
This study is testing if using individual blood tests and imaging can help doctors create better treatment plans for people with certain types of lymphoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT04417803 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients diagnosed with specific types of lymphomas, including diffuse large B-cell lymphoma, Hodgkin's lymphoma, and follicular lymphoma. It aims to enhance treatment strategies by utilizing high-throughput molecular techniques to identify tumor genotypes and individual biomarkers. The approach involves blood sampling and the use of PET imaging to optimize treatment plans based on patient responses. By integrating these methods, the study seeks to improve patient management and outcomes during and after treatment.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with diffuse large B-cell lymphoma, Hodgkin's lymphoma, or follicular lymphoma who are not currently undergoing treatment.
Not a fit: Patients with localized lymphoma that has been treated surgically or with localized radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for lymphoma patients.
How similar studies have performed: Other studies have shown promise in using molecular techniques and PET imaging for personalized treatment approaches in lymphomas, indicating a potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Person who has not opposed to their inclusion in the trial * Confirmation of the diagnosis of one of the lymphomas (DGLBL, LF, classic LH, LT or LCM) according to the WHO 2016 international classification (Smerdlow et al, 2016) * Patients not currently taking treatment for their haemopathy (or who have received corticosteroid therapy alone within 14 days prior to the 1st sampling, dose limited to 500mg total) * Patients requiring systemic treatment within 30 days of screening Exclusion Criteria: * Person subject to legal protection (curatorship, guardianship) * Person under partial judicial control * Pregnant, parturient or breastfeeding woman * Adult incapable or incapable to express his or her non-opposition * Minor * Localized lymphoma treated by surgery and/or localized radiotherapy
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Cédric ROSSI
- Email: cedric.rossi@chu-dijon.fr
- Phone: 0380295041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.